Rapid progress in genomic sequencing and high-throughput methods has made the molecular characterization of many complex diseases, especially cancer, possible. Ongoing international efforts have focused on collecting and sequencing a wide variety of human neoplasms and documenting the interaction between therapeutic compounds and genetic alterations. The analysis and integration of these vast amounts of data has, in turn, prompted complex problems with solutions requiring advanced quantitative, systems-level approaches.
At the Center for Systems and Computational Biology (CSCB) at Rutgers Cancer Institute of New Jersey, a group of computational biologists, geneticists, molecular pathologists, and clinical oncologists developing new quantitative and experimental approaches to improve diagnosis, understand disease pathogenesis, discover new disease-driving aberrations, and design effective clinical trials and precise treatment strategies for patients under active care. To this end, the Center takes advantage of high-throughput experimental facilities and high-performance computing resources at Rutgers University, and extensively collaborates with scientists at the Rutgers Discovery Informatics Institute (RDI2), the Institute for Quantitative Biomedicine at Rutgers (IQB@R), and the Human Genetics Institute of New Jersey (HGINJ) in designing and implementing precision medicine approaches.